Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | $178K | $171K | $1.95M | $3.45M | $9.10M |
| Revenue growth | — | — | — | — | — | — | -3.9% | 1040.7% | 76.9% | 163.5% |
| Gross profit | — | — | — | — | — | -$97.7K | -$70.8K | $457K | $1.08M | $5.14M |
| Gross margin | — | — | — | — | — | -54.9% | -41.4% | 23.4% | 31.3% | 56.5% |
| Operating income | -$32.6K | — | — | -$5.81M | -$4.90M | -$10.2M | -$10.0M | -$12.0M | -$11.9M | -$4.23M |
| Operating margin | — | — | — | — | — | -5735.9% | -5860.2% | -612.3% | -344.3% | -46.5% |
| Net income | -$47.8K | — | — | -$6.78M | -$13.6M | -$9.95M | -$10.00M | -$11.9M | -$12.3M | -$3.61M |
| Net margin | — | — | — | — | — | -5584.3% | -5842.0% | -607.4% | -356.7% | -39.6% |
| EPS (diluted) | -$0.01 | — | — | -$0.57 | -$2.52 | -$0.93 | -$0.63 | -$0.65 | -$0.46 | -$0.09 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.1K | — | — | -$5.40M | -$3.43M | -$8.60M | -$7.52M | -$12.9M | -$11.0M | -$2.84M |
| Capital expenditures | — | — | — | $58.4K | $122K | $67.1K | $275K | $384K | $120K | $81.7K |
| Free cash flow | — | — | — | -$5.45M | -$3.55M | -$8.67M | -$7.79M | -$13.3M | -$11.1M | -$2.92M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $26.5K | $13.3K | $261K | $4.04M | $6.90M | $8.16M | $5.32M | $1.46M | $6.57M |
| Total assets | $757K | $250K | $219K | $533K | $4.76M | $7.94M | $12.8M | $8.10M | $5.37M | $10.8M |
| Total liabilities | $1.02M | $5.29M | $4.61M | $1.77M | $2.69M | $1.38M | $3.22M | $1.85M | $4.55M | $3.71M |
| Shareholders' equity | -$266K | -$5.04M | -$4.40M | -$1.24M | $2.07M | $6.55M | $9.60M | $6.25M | $822K | $7.07M |
| Retained earnings | -$266K | -$5.32M | -$10.5M | -$17.2M | -$30.9M | -$40.8M | -$50.8M | -$62.7M | -$75.0M | -$78.6M |
| Shares (wtd avg diluted) | 5.22M | 7.86M | 9.66M | 13.5M | 7.39M | 10.7M | 16.0M | 18.1M | 26.8M | 40.2M |
Every figure is extracted from NEUROONE MEDICAL TECHNOLOGIES Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.